| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JSS.2009.05.032 |
| P8608 | Fatcat ID | release_spjz6p3iuzcbnnhoy2yf3qgm6y |
| P932 | PMC publication ID | 2795050 |
| P698 | PubMed publication ID | 19765735 |
| P5875 | ResearchGate publication ID | 26823209 |
| P2093 | author name string | Herbert Chen | |
| Scott N Pinchot | |||
| Muthusamy Kunnimalaiyaan | |||
| Mackenzie R Cook | |||
| Jui-yu Chen | |||
| P2860 | cites work | Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. | Q53554047 |
| Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? | Q74770146 | ||
| ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells | Q83126018 | ||
| Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat | Q83287884 | ||
| Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells | Q24323223 | ||
| Carcinoid tumors | Q24614827 | ||
| The proteasome: a novel target for cancer chemotherapy | Q28215095 | ||
| Lithium ions: a novel treatment for pheochromocytomas and paragangliomas | Q28582101 | ||
| The role of p27Kip1 in proteasome inhibitor induced apoptosis. | Q34229096 | ||
| Ubiquitin proteasome pathway: implications and advances in cancer therapy | Q34446282 | ||
| Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. | Q34662451 | ||
| Proteasome inhibitors as new anticancer drugs | Q34985261 | ||
| The proteasome: a suitable antineoplastic target | Q35762448 | ||
| Pathways to caspase activation | Q36153989 | ||
| Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways | Q36334183 | ||
| Treatment of advanced carcinoid tumors | Q36343258 | ||
| Bortezomib: proteasome inhibition as an effective anticancer therapy | Q36366801 | ||
| Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. | Q39561199 | ||
| Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells | Q40158471 | ||
| Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells | Q40302603 | ||
| Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. | Q40393503 | ||
| ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells | Q40409837 | ||
| Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells | Q40444210 | ||
| Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer | Q40584955 | ||
| Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells | Q40715403 | ||
| Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells | Q44506841 | ||
| The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. | Q46120621 | ||
| P433 | issue | 1 | |
| P921 | main subject | carcinoid tumor | Q1734755 |
| phenotype | Q104053 | ||
| P304 | page(s) | 15-19 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Journal of Surgical Research | Q15763329 |
| P1476 | title | MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype | |
| P478 | volume | 158 |
| Q36167254 | Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids |
| Q28246704 | Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours |
| Q26860284 | Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies? |
| Q47393972 | Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets |
| Q37833109 | The molecular pathogenesis and management of bronchial carcinoids |
| Q38003074 | Translation of molecular pathways into clinical trials of neuroendocrine tumors |
Search more.